Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) Interest Expense : $-0.00 Mil (TTM As of Mar. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Satsuma Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Satsuma Pharmaceuticals's interest expense for the three months ended in Mar. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Satsuma Pharmaceuticals's Operating Income for the three months ended in Mar. 2023 was $ -10.77 Mil. Satsuma Pharmaceuticals's Interest Expense for the three months ended in Mar. 2023 was $ 0.00 Mil. Satsuma Pharmaceuticals has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Satsuma Pharmaceuticals Interest Expense Historical Data

The historical data trend for Satsuma Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satsuma Pharmaceuticals Interest Expense Chart

Satsuma Pharmaceuticals Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Interest Expense

Get a 7-Day Free Trial

-0.09

-0.48

-0.35

-0.16

-0.01

Satsuma Pharmaceuticals Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Interest Expense	Get a 7-Day Free Trial															-0.01	-	-	-	-

Satsuma Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

Satsuma Pharmaceuticals (NAS:STSA) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Satsuma Pharmaceuticals's Interest Expense for the three months ended in Mar. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2023 was $-10.77 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2023 was $0.00 Mil.

Satsuma Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2023 is calculated as

Satsuma Pharmaceuticals had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Satsuma Pharmaceuticals (Satsuma Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satsuma Pharmaceuticals Inc (NAS:STSA) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Oyster Point Boulevard, Suite 221, South San Francisco, CA, USA, 94080

Website

https://www.satsumarx.com

Satsuma Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.

Executives

Mutya Harsch	director	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704
Shin Nippon Biomedical Laboratories, Ltd.	10 percent owner	2438 MIYANOURA-MACHI, KAGOSHIMA CITY, KAGOSHIMA M0 891-1394
Thomas P Soloway	director	C/O AUDENTES THERAPEUTICS, INC., 600 CALIFORNIA ST., 17TH FLOOR, SAN FRANCISCO CA 94108
Ken Takanashi	director, 10 percent owner	C/O WAVE LIFE SCIENCES LTD., 733 CONCORD AVE., CAMBRIDGE MA 02138
Braden Michael Leonard	10 percent owner	156 S. FIRST STREET, ZIONSVILLE IN 46077
Commodore Capital Lp	10 percent owner	444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Detlef Albrecht	officer: Chief Medical Officer	SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080
Thomas P. O'neil	officer: Chief Financial Officer	SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080
Rajeev M. Shah	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Tpg Group Holdings (sbs) Advisors, Inc.	10 percent owner	C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Heath Lukatch	director	326 BOLLAY DRIVE, GOLETA CA 93117
John A Kollins	director, officer: President and CEO	SATSUMA PHARMACEUTICALS, INC., 400 OYSTER POINT BOULEVARD, SUITE 221, SOUTH SAN FRANCISCO CA 94080